Safety and effi cacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial

Jacob P. Lalezari, Gulam H. Latiff, Cynthia Brinson, Juan Echevarría, Sandra Treviño-Pérez, Johannes R. Bogner, Melanie Thompson, Jan Fourie, Otto A.Sussmann Pena, Fernando C.Mendo Urbina, Marcelo Martins, Iulian G. Diaconescu, David A. Stock, Samit R. Joshi, George J. Hanna, Max Lataillade, Javier D. Altclas, Gerardo Amaya-Tapia, Jaime F. Andrade-Villanueva, Victoria AramaAIvaro Arango-Duque, Keikawus Arasteh, Jose Arribas, Rogelio Bardinas-Rodriguez, Carlos M. Benites-Villafane, Johannes Bogner, Pedro E. Cahn, Wilfredo M. Casapia-Morales, Lidia I. Cassetti, Bonaventura Clotet, Edwin DeJesus, Juan I. Echevarria, Richard Elion, Jerome Ernst, Judith Feinberg, Jorge Galindez, M. Gatell, Enrique R. Granados-Reyes, Shawn Hassler, Charles Hicks, David Johnson, Richard Kaplan, Jacob Lalezari, Javier R. Lama-Valdivia, Alberto M.La Rosa Rodriguez, Mey Leon, Sergio H. Lupo, Francisco Marquez-Diaz, Marcelo D. Martins, Mehri Mckellar, Fernando C. Mendo-Urbina, Yvett Pinedo-Ramirez, Liviu J. Prisacariu, Juergen Rockstroh, Sorin Rugina, Magno R. Salazar-Castro, Anita R. Scribner, Juan G. Sierra-Madero, Louis M. Sloan, Albrecht Stoehr, Otto A. Sussmann-Pena, Pablo Tebas, Sandra C. Trevino-Perez, Olga A. Tsybakova, Evgeny E. Voronin, Alexey A. Yakovlev, Natalia G. Zakharova

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

57 Citas (Scopus)

Huella

Profundice en los temas de investigación de 'Safety and effi cacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial'. En conjunto forman una huella única.

Pharmacology, Toxicology and Pharmaceutical Science